Pacific Biosciences Of California (PACB) Non-Current Assets (2010 - 2026)

Pacific Biosciences Of California's Non-Current Assets history runs 17 years deep, the most recent figure standing at $412.8 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 0.73% year-over-year to $412.8 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 43.89% decrease from a year earlier, with the FY2025 full-year figure at $409.0 million, down 46.52% from the prior year.
• Non-Current Assets climbed to $412.8 million in Q1 2026 per PACB's latest filing, from $409.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $1.0 billion in Q3 2023 and bottomed at $408.9 million in Q3 2025.
• The 5-year median for Non-Current Assets is $905.1 million (2022), against an average of $767.3 million.
• Across the five-year window, Non-Current Assets surged 1499.18% in 2022 and slumped 58.12% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $915.0 million in 2022, then increased by 9.72% to $1.0 billion in 2023, then slipped by 23.83% to $764.8 million in 2024, then tumbled by 46.52% to $409.0 million in 2025, then increased by 0.93% to $412.8 million in 2026.
• Per Business Quant, the three latest PACB Non-Current Assets figures stand at $412.8 million (Q1 2026), $409.0 million (Q4 2025), and $408.9 million (Q3 2025).